PHARMING GROUP N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.6 USD | +0.04% |
|
+1.90% | -24.76% |
| Sales 2024 * | 266M 285M 392M | Sales 2025 * | 305M 326M 448M | Capitalization | 500M 536M 736M |
|---|---|---|---|---|---|
| Net income 2024 * | -10M -10.71M -14.71M | Net income 2025 * | 4M 4.28M 5.88M | EV / Sales 2024 * | 1.55 x |
| Net cash position 2024 * | 88.21M 94.46M 130M | Net cash position 2025 * | 95.91M 103M 141M | EV / Sales 2025 * | 1.33 x |
| P/E ratio 2024 * |
-46.4
x | P/E ratio 2025 * |
-186
x | Employees | 382 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharming Group N.V.
More recommendations
More press releases
| 1 day | +0.04% | ||
| 1 week | +1.90% | ||
| Current month | -6.01% | ||
| 1 month | -9.95% | ||
| 3 months | -25.14% | ||
| 6 months | -27.12% | ||
| Current year | -24.76% |
1 week
7.67
8.81
1 month
7.6710.00
Current year
7.6713.20
1 year
7.6716.71
3 years
6.1017.81
5 years
6.1021.99
10 years
6.1021.99
| Managers | Title | Age | Since |
|---|---|---|---|
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
Jeroen Wakkerman
DFI | Director of Finance/CFO | 55 | 20-11-15 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Pykett
BRD | Director/Board Member | 60 | 20-12-10 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-05-18 |
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 8.6 | +0.04% | 12,485 |
| 24-06-13 | 8.596 | +2.28% | 1,144 |
| 24-06-12 | 8.405 | -1.58% | 8,277 |
| 24-06-11 | 8.54 | +4.27% | 1,714 |
| 24-06-10 | 8.19 | -2.96% | 2,341 |
Delayed Quote Nasdaq, June 14, 2024 at 04:30 pm
More quotes
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.743
EUR
Average target price
1.875
EUR
Spread / Average Target
+152.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.64% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +17.55% | 246B | |
| 0.00% | 225B | |
| +10.50% | 218B | |
| +3.68% | 160B | |
| -4.38% | 156B |
- Stock Market
- Equities
- PHARM Stock
- PHAR Stock
